CGEM · Cullinan Therapeutics Inc
United States · RS rating 64 · As of 2026-11-03
| Price | 15.75 USD |
|---|---|
| 1-day change | +5.5% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 52 / 45 / 92 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 38 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +31.4% |
| Market cap (USD) | $783.8M |